AIA
ALT icon

Allied Investment Advisors’s Altimmune ALT Stock Holding History

Allied Investment Advisors’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24,350
Closed -$274K – 71
2023
Q4 		$274K Buy
+24,350
New +$102K 0.07% 55

Other funds holding ALT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Allied Investment Advisors's ALT Position: Q1 2024 in Review

Allied Investment Advisors sold out of Altimmune (ALT) in Q1 2024, closing a stake of 24,350 shares — an estimated $274K sold.

Allied Investment Advisors first reported a position in ALT in Q4 2023 and held it in 1 quarter. The position peaked at $274K in Q4 2023. 172 funds tracked by Wall St. Rank hold ALT as of Q1 2024.

  • Allied Investment Advisors reported no remaining Altimmune position as of Q1 2024 after selling out during the quarter.
  • Allied Investment Advisors sold 24,350 Altimmune shares in Q1 2024, an estimated $274K.
  • Allied Investment Advisors first reported a position in Altimmune in Q4 2023 and held it in 1 quarter.
  • Allied Investment Advisors's Altimmune position peaked at $274K in Q4 2023.
  • 172 funds tracked by Wall St. Rank held Altimmune as of Q1 2024.

Based on Allied Investment Advisors's 13F filing for Q1 2024, filed 11 Apr 2024.